Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 2Phase 3 1

Status

Completed 3Terminated 1Recruiting 1

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Genitourinary 5

Conditions

Carcinoma, Non-Small-Cell Lung 244Lung Neoplasms 60Neoplasms 58Head and Neck Neoplasms 57Stomach Neoplasms 56Squamous Cell Carcinoma of Head and Neck 48Parkinson Disease 4, Autosomal Dominant Lewy Body 44Neoplasm Metastasis 41Small Cell Lung Carcinoma 38Urinary Bladder Neoplasms 28Uterine Cervical Neoplasms 26Esophageal Neoplasms 25Colorectal Neoplasms 25Cholangiocarcinoma 24Carcinoma 24Biliary Tract Neoplasms 24Ovarian Neoplasms 21Carcinoma, Transitional Cell 18Carcinoma, Squamous Cell 17Recurrence 16Esophageal Squamous Cell Carcinoma 16Melanoma 13Breast Neoplasms 13Non-Squamous Non-Small Cell Lung Cancer 12Mesothelioma, Malignant 12Mesothelioma 12Nasopharyngeal Carcinoma 11Endometrial Neoplasms 11Adenocarcinoma 11Pancreatic Neoplasms 10

Interventions

Gemcitabine 7Cisplatin 5pembrolizumab 4enfortumab vedotin 4Mitomycin 4Trastuzumab 3Pemetrexed 3Carboplatin 3dodecyl maltoside 2atezolizumab 2Sunitinib 2vinflunine 1valrubicin 1tucatinib 1palbociclib 1niraparib 1motexafin gadolinium 1cabozantinib 1avelumab 1apatorsen 1Water 1VMBP protocol 1Standard of Care 1Radiation Dose Hypofractionation 1Nivolumab 1Neoadjuvant Therapy 1Immunoglobulins, Intravenous 1Gels 1GSK-3326595 1Fulvestrant 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
INDUSTRY × Urologic Neoplasms × Cisplatin × Clear all
NCT07566156 2026-06-08

EV-309

Astellas Pharma Inc

Phase 3 Recruiting
390 enrolled
Genitourinary

Urogenital Diseases, Urinary Bladder Diseases, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Neoplasms, Neoplasms by Site, Urogenital Neoplasms, Urologic Diseases, Urologic Neoplasms, Female Urogenital Diseases, Male Urogenital Diseases

NCT03288545 2026-03-24

EV-103

Astellas Pharma Inc

Phase 1/2 Terminated
348 enrolled 1 FDA
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms, Urologic Neoplasms

NCT01454089 2016-10-07

A Phase 2 Study Comparing Chemotherapy in Combination With OGX-427 or Placebo in Patients With Bladder Cancer

Achieve Life Sciences

Phase 2 Completed
183 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Urologic Neoplasms

NCT02006667 2015-02-11

A Study of Herceptin (Trastuzumab) Combination Therapy in Patients With Metastatic Urothelial Cancer

Hoffmann-La Roche

Phase 2 Completed
13 enrolled 12 charts
Genitourinary

Urologic Neoplasms

NCT00374868 2010-11-04

Pemetrexed Plus Cisplatin Bi-Weekly, in Patients With Urothelial Cancer (Metastatic, Locally Advanced or Non-Resectable)

Eli Lilly and Company

Phase 1/2 Completed
59 enrolled 17 charts
Genitourinary

Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡